Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CORT125329 in Healthy Subjects
NCT04672512Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zavacorilant in obesity and metabolic syndrome (7 arms), sponsored by Corcept Therapeutics. Primary endpoints: Percentage of Participants with One or More Adverse Events at Day 23, Percentage of Participants with One or More Serious Adverse Events at Day 23 and 1 more. Started Oct 2020; status: completed.
02
Drugs
zavacorilant
03
Conditions
obesitymetabolic syndrome
Beyond the preview
Go deeper on NCT04672512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672512.